E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the bioavailability of:
5 x 1 mg everolimus intact tables, and
5 x 1 mg everolimus tablets suspended in 30 mL of water |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the safety and tolerability of the 1 mg everolimus tablets administered as suspension and as intact tablets |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Female or male healthy subjects from 18 to 55 years of age;
• Female subjects must be postmenopausal (no menstrual bleeding for 12 months), or surgically sterilized at least 6 months prior to screening;
• Good health status as determined by past medical history, physical examination, vital signs, electrocardiogram and laboratory tests within normal ranges at screening;
• Vital signs (after 3 minutes resting measured in the supine position) must be within the ranges specified in the protocol |
|
E.4 | Principal exclusion criteria |
• Smokers defined as having used tobacco products in the previous 3 months or having urine cotinine levels greater than 500 ng/mL tested at screening and each baseline visit;
• Use of any prescription medication within 1 month prior to dosing or any over-the-counter (OTC) medication within 2 weeks prior to dosing;
• Consumption of grapefruit products within 1 week prior to dosing;
• Participation in any clinical investigation within 4 weeks prior to dosing;
• Donation or loss of 450 mL or more of blood within 56 days prior to dosing;
• Women who are of child-bearing potential, or pregnant, or breast feeding (positive serum pregnancy test for β-hCG at screening and each baseline visit);
• A known hypersensitivity to rapamycins and their derivates or drugs similar to RAD001, e.g. macrolides;
• Any subject who has been diagnosed with type I or II diabetes, hyperglycemia or impaired glucose intolerance;
• History of any significant respiratory system chronic brochospastic disease (including asthma and COPD, treated or not treated).
• History of atopic allergy (asthma, urticaria, eczematous dermatitis);
• Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs or which may jeopardize the subject in case of participation in the study.
• History of immunosuppression, including a known positive HIV test result;
• A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result;
• Evidence of alcohol and drug usage as indicated by laboratory assays performed at screening and prior to baseline period. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary pharmacokinetic parameters: AUC(0-t), AUC(0-inf) and Cmax |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Full pharmacokinetic whole blood samples will be drawn at each of the two treatment periods as follows: 1 pre-dose sample < 15min prior to administration of study drug and 17 postdose
samples at 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 36 h, 48 h, 72 h, 96 h, 120 h and 144 h after administration of study drug. |
|
E.5.2 | Secondary end point(s) |
- Secondary pharmacokinetic parameters: Tmax, λz, Vd/F, CL/F and t1/2
- Safety endpoints (evaluation of adverse events and serious adverse events, vital signs, ECG, laboratory results (hematology, blood chemistry, urinalysis) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
- Full pharmacokinetic whole blood samples will be drawn at each of the two treatment periods as follows: 1 pre-dose sample < 15min prior to administration of study drug and 17 postdose
samples at 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 36 h, 48 h, 72 h, 96 h, 120 h and 144 h after administration of study drug.
- Safety laboratory assessments will be performed regularly. Hematology and biochemistry laboratory parameters will be evaluated at screening, each of the 2 baseline visits, 144 hours post-dose and at the study completion visit. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
|
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
Will this trial be conducted at a single site globally?
| Yes |
E.8.4 | Will this trial be conducted at multiple sites globally? | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 2 |
E.8.9.2 | In all countries concerned by the trial days | 0 |